<DOC>
	<DOCNO>NCT00000658</DOCNO>
	<brief_summary>To determine impact dose intensity tumor response survival patient HIV-associated non-Hodgkin 's lymphoma ( NHL ) . HIV-infected patient increase risk develop intermediate high-grade NHL . While combination chemotherapy aggressive B-cell NHL absence immunodeficiency highly effective , outcome therapy patient AIDS-associated NHL disappointing . Treatment frequently complicate occurrence multiple opportunistic infection , well presence poor bone marrow reserve , make administration standard dose chemotherapy difficult . A recent study complete use low-dose modification standard mBACOD ( cyclophosphamide , doxorubicin , vincristine , bleomycin , dexamethasone , methotrexate ) treatment . A 46 percent response rate observe patient treated combination chemotherapeutic agent , number durable remission reduce toxicity compare previous experience standard treatment . A subsequent study show similar effectiveness use low dose methotrexate administer day 15 . It hop use sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) improve bone marrow function allow administration high dose chemotherapy .</brief_summary>
	<brief_title>A Phase III Randomized Trial Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF Treatment AIDS-Associated Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>HIV-infected patient increase risk develop intermediate high-grade NHL . While combination chemotherapy aggressive B-cell NHL absence immunodeficiency highly effective , outcome therapy patient AIDS-associated NHL disappointing . Treatment frequently complicate occurrence multiple opportunistic infection , well presence poor bone marrow reserve , make administration standard dose chemotherapy difficult . A recent study complete use low-dose modification standard mBACOD ( cyclophosphamide , doxorubicin , vincristine , bleomycin , dexamethasone , methotrexate ) treatment . A 46 percent response rate observe patient treated combination chemotherapeutic agent , number durable remission reduce toxicity compare previous experience standard treatment . A subsequent study show similar effectiveness use low dose methotrexate administer day 15 . It hop use sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) improve bone marrow function allow administration high dose chemotherapy . Patients randomize one two treatment group . Patients stratify ( 1 ) presence absence prior AIDS diagnosis , ( 2 ) Karnofsky performance status 70 great low 70 . Treatment include prophylaxis meningeal lymphoma Pneumocystis carinii pneumonia . Patients low-dose mBACOD experience neutropenia may give rGM-CSF absolute neutrophil count improve . AZT may initiate completion chemotherapy patient complete remission time . PER AMENDMENT 5/30/95 : This trial close accrual 11/7/94 recommendation Data Safety Monitoring Board ( DSMB ) , non-significant difference survival 2 treatment group expect change enrollment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis Bactrim , aerosolize pentamidine , dapsone . Allowed : ddI , except patient also take allopurinol . Patients must follow : Diagnosis HIV seropositivity nonHodgkin 's lymphoma . Ability give inform consent willingness comply procedure visit schedule . If age 12 18 must receive care direct supervision pediatric oncologist , consent parent , guardian , person power attorney . Participation clinical trial antiretroviral agent discretion investigator individual patient . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection , exclude Mycobacterium avium complex , require antibiotic therapy . Another prior current malignancy , except curatively treat cervical basal cell carcinoma . Kaposi 's sarcoma rapidly progressive , visceral involvement , cause peripheral edema . Primary central nervous system lymphoma . Concurrent Medication : Excluded : Zidovudine ( AZT ) antiretroviral agent unless allow investigator . ddI allow except also take allopurinol . Systemic myelosuppressive drug , include trimethoprim/sulfamethoxazole ( T/S ) , pyrimethamine/sulfa , ganciclovir . Patients follow exclude : Active opportunistic infection , exclude Mycobacterium avium complex , require antibiotic therapy . Another prior current malignancy , except curatively treat cervical basal cell carcinoma . Kaposi 's sarcoma rapidly progressive , visceral involvement , cause peripheral edema . Primary central nervous system lymphoma . Prior Medication : Excluded : Immunomodulating agent within 2 week study entry . Prior Treatment : Excluded : Chemotherapy . Radiation therapy outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>M-BACOD protocol</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
</DOC>